EMEA-001811-PIP02-15-M04

Key facts

Active substance
ligelizumab
Therapeutic area
Dermatology
Decision number
P/0308/2021
PIP number
EMEA-001811-PIP02-15-M04
Pharmaceutical form(s)
  • Solution for injection
  • Age-appropriate dosage form for parenteral use
Condition(s) / indication(s)
Treatment of chronic spontaneous urticaria
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novartis EuroPharm Ltd.

Tel.: +41 613241111
E-mail: paediatric.enquiries@novartis.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating